Back to top
more

Glaukos (GKOS)

(Real Time Quote from BATS)

$89.14 USD

89.14
462,289

+1.08 (1.23%)

Updated Aug 6, 2025 12:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.

Zacks Equity Research

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 46.15% and 5.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa

by Zacks Equity Research

Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?

by Zacks Equity Research

GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.

Zacks Equity Research

Glaukos Stocks Rides on Strong Product Demand Amid Competition

by Zacks Equity Research

GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales

by Zacks Equity Research

Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.

Zacks Equity Research

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 0% and 8.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?

by Indrajit Bandyopadhyay

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?

by Zacks Equity Research

In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.

Zacks Equity Research

Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?

by Zacks Equity Research

Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.

Zacks Equity Research

Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn into More Strength?

by Zacks Equity Research

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?

by Zacks Equity Research

Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.

Zacks Equity Research

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.